IA Trial Radar | ||
|---|---|---|
L'essai clinique NCT06628453 (CGM2) pour Diabète Sucré de Type 2 (T2DM), Grossesse est en recrutement. Consultez la vue en carte du Radar des Essais Cliniques et les outils de découverte par IA pour tous les détails, ou posez vos questions ici. | ||
Un essai clinique correspond aux filtres sélectionnés
Vue en carte
CGM for Management of Type 2 Diabetes in Pregnancy (CGM2) 564
Les détails de l'essai clinique sont principalement disponibles en anglais. Cependant, l'IA Trial Radar peut vous aider ! Cliquez simplement sur 'Expliquer l'étude' pour voir et discuter des informations sur l'étude dans la langue sélectionnée.
L'essai clinique NCT06628453 (CGM2) est une étude interventionnel pour Diabète Sucré de Type 2 (T2DM), Grossesse. Son statut actuel est : en recrutement. L'étude a débuté le 8 avril 2025 et vise à recruter 564 participants. Dirigée par l'Université de l'Alabama à Birmingham, l'étude devrait être terminée d'ici le 1 juillet 2029. Les données du site ClinicalTrials.gov ont été mises à jour pour la dernière fois le 15 juin 2025.
Résumé succinct
The goal of this clinical trial is to learn if continuous glucose monitoring works better than self-monitoring of blood glucose (fingersticks) to treat type 2 diabetes in pregnancy. It will also learn about all risk factors (biologic, personal, social) for maternal and infant complications in type 2 diabetes pregnancies. The main questions it aims to answer are:
- Does continuous glucose monitoring improve infant o...
Description détaillée
We will conduct a multicenter, open-label randomized controlled trial of pregnant individuals with T2DM to test the effectiveness of CGM at improving maternal and neonatal outcomes, compared to SMBG. All pregnant women who have T2DM will be screened for eligibility. If a patient is eligible, the study will be explained to them and if they consent to participate, they will be randomized centrally in a 1:1 ratio to CGM...Afficher plus
Titre officiel
Continuous Glucose Monitoring for Management of Type 2 Diabetes in Pregnancy
Pathologies
Diabète Sucré de Type 2 (T2DM)GrossessePublications
Articles scientifiques et travaux de recherche publiés sur cet essai clinique:Autres identifiants de l'étude
- CGM2
- IRB-300013640
- 1R01HD113612 (Subvention/contrat NIH (É.-U.))
Numéro NCT
Date de début (réel)
2025-04-08
Dernière mise à jour publiée
2025-06-15
Date de fin (estimée)
2029-07
Inscription (estimée)
564
Type d'étude
Interventionnel
PHASE
N/A
Statut
En recrutement
Mots clés
Diabetes
Pregnancy
CGM
Pregnancy
CGM
Objectif principal
Traitement
Méthode d'allocation
Randomisé
Modèle d'intervention
Parallèle
Masquage
Aucun (ouvert)
Bras / Interventions
| Groupe de participants/Bras | Intervention/Traitement |
|---|---|
ExpérimentalContinuous Glucose Monitoring Real-time continuous glucose monitoring | CGM Real-time continuous glucose monitoring |
Aucune interventionSelf-Monitoring of Blood Glucose Self-monitoring of blood glucose (standard of care) | N/A |
Critère principal d'évaluation
Critère secondaire d'évaluation
| Critères d'évaluation | Description de la mesure | Période |
|---|---|---|
Time in Range (TIR) at 34 weeks gestation | Percentage of time spent within target range (63-140mg/dL) on Continuous Glucose Monitoring at 34 weeks gestation | 33 to 35 weeks gestation |
Composite Neonatal Morbidity | Composite morbidity of the neonate including one or more of preterm birth (delivery less than 37 weeks for any indication), birth trauma (shoulder dystocia with nerve injury, clavicular or humeral fracture or 3 or more maneuvers to resolve), hypoglycemia (requiring treatment with dextrose gel or IV within 24 hours of birth), hyperbilirubinemia (requiring phototherapy within 72 hours of birth), large-for-gestational-age infant (birthweight greater than the 90th percentile for gestational age), and miscarriage, stillbirth or neonatal death prior to hospital discharge. | From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life |
| Critères d'évaluation | Description de la mesure | Période |
|---|---|---|
Preterm birth | Delivery less than 37 weeks gestation | Delivery |
Birth trauma | Shoulder dystocia with nerve injury, clavicular or humeral fracture or 3 or more maneuvers to relieve | Delivery |
Neonatal hypoglycemia | Low neonatal glucose requiring treatment with dextrose gel or IV within 24 hours of life | Delivery to 24 hours of life |
Hyperbilirubinemia | Elevated bilirubin requiring phototherapy within 72 hours of life | Delivery to 72 hours of life |
Large-for-gestational-age (LGA) neonate | Birthweight greater than the 90th percentile for gestational age | Delivery |
Small-for-gestational-age (SGA) neonate | Birthweight less than the 10th percentile for gestational age | Delivery |
Fetal glucose | Concentration of umbilical cord blood glucose (mg/dL) | Delivery |
Fetal insulin | Concentration of umbilical cord blood insulin (uU/mL) | Delivery |
Fetal C-peptide | Concentration of umbilical cord blood C-peptide (ng/mL) | Delivery |
Fetal leptin | Concentration of umbilical cord blood leptin (ng/mL) | Delivery |
Fetal ghrelin | Concentration of umbilical cord blood ghrelin (uU/L) | Delivery |
Fetal surfactant protein D | Concentration of umbilical cord blood surfactant protein D (ng/mL) | Delivery |
Time Above Range (TAR) at 34 weeks | Percentage of time spent above range greater than 140mg/dL on Continuous Glucose Monitoring (CGM) at 34 weeks | 33 to 35 weeks |
Time Below Range (TBR) at 34 weeks | Percentage of time spent below range less than 63mg/dL on Continuous Glucose Monitoring at 34 weeks | 33 to 35 weeks |
Mean glucose at 34 weeks | Average glucose in mg/dL using Continuous Glucose Monitoring data at 34 weeks | 33 to 35 weeks |
Glucose Management Indicator (GMI) | Glucose management indicator as an estimate of hemoglobin A1c calculated using mean glucose on CGM at 34 weeks | 33 to 35 weeks |
Glucose variability at 34 weeks | Coefficient of variation calculated as the mean glucose divided by standard deviation using Continuous Glucose Monitoring data at 34 weeks | 33 to 35 weeks |
Mean fasting glucose at 34 weeks | Average glucose at 6-7am on Continuous Glucose Monitoring at 34 weeks | 33 to 35 weeks |
Hemoglobin A1c at Delivery | Hemoglobin A1c (%) at delivery | Delivery |
Insulin total daily dose at delivery | Total number of units of insulin taken per day at time of delivery | Delivery |
Cesarean delivery | First cesarean delivery or cesarean delivery after a history of prior cesarean | Delivery |
Glucose Monitoring Satisfaction | Score on glucose monitoring satisfaction survey at delivery | Delivery |
Fetal or neonatal death | Miscarriage (pregnancy loss less than 20 weeks), stillbirth (fetal death at 20 weeks or more), or neonatal death (death after birth up to 28 days of life) | From the date of randomization to the date of neonatal hospital discharge, assessed up to 12 months of life |
Neonatal Intensive Care Unit (NICU) Admission | Admission to the neonatal intensive care unit with length of stay greater than 24 hours | From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life |
Neonatal length of stay | Duration of neonatal hospitalization after delivery | From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life |
Neonatal mechanical ventilation | Neonate requiring intubation and mechanical ventilation for respiratory support | From the date of delivery to the date of neonatal hospital discharge, assessed up to 12 months of life |
Insulin increase during pregnancy | Percentage change in total daily dose of insulin at delivery compared to enrollment | From the date of randomization to the date of delivery, assessed up to 9 months |
Preeclampsia | Elevated blood pressure greater than 140/90 mmHg after 20 weeks gestation with proteinuria or other severe features by ACOG criteria (may be superimposed on chronic hypertension or not) | From the date of randomization to the date of maternal hospital discharge after delivery, assessed up to 9 months |
Postpartum infection | Developing one or more of endometritis, wound infection or other wound complication such as seroma, hematoma or dehiscence) | From the date of delivery through 6 weeks' postpartum |
Glucose Monitoring Adherence | Defined as percentage of expected self-monitoring of blood glucose (SMBG) values completed based on recommended 4 values per day for participants in the SMBG arm and percentage of time Continuous Glucose Monitoring (CGM) in use in the CGM arm | From the date of randomization to the date of delivery, assessed up to 9 months |
Assistant à la participation
Critères d'éligibilité
Âges éligibles
Adulte
Âge minimum
18 Years
Sexes éligibles
Femme
- Type 2 diabetes mellitus treated with daily insulin injections or oral hypoglycemic agents diagnosed before pregnancy or at less than 14 weeks gestation with hemoglobin A1c 6.5% or greater
- Pregnant with viable fetus at 6 to less than 23 weeks gestation
- Maternal age 18-50 years old
- Unable or unwilling to wear CGM due to intolerance to medical-grade adhesives or skin conditions
- Multiple gestation
- Major fetal anomaly or two or more minor fetal anomalies
- Planned delivery outside study consortium
- Participating in another conflicting interventional study
- Participation in this trial in a previous pregnancy
- Patient unable to consent
- Physician refusal for other reasons
National Institutes of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Partie responsable de l'étude
Ashley N. Battarbee, Investigateur principal, Associate Professor, University of Alabama at Birmingham
Contact central de l'étude
Contact: Ashley Battarbee, MD, MSCR, 205-975-2361, [email protected]
7 Centres de l'étude dans 1 pays
Alabama
University of Alabama at Birmingham, Birmingham, Alabama, 35233, United States
Ashley Battarbee, Contact, 205-975-2361, [email protected]
En recrutement
California
University of California at San Diego, San Diego, California, 92121, United States
Gladys Ramos, MD, Contact, 858-657-7200, [email protected]
En recrutement
North Carolina
University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, 27599, United States
Kim Boggess, MD, Contact, 919-966-2131, [email protected]
En recrutement
Oregon
Oregon Health and Science University, Portland, Oregon, 97213, United States
Amy Valent, DO, MCR, Contact, 503-418-4200, [email protected]
En recrutement
Pennsylvania
University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States
Celeste Durnwald, MD, Contact, 800-789-7366, [email protected]
En recrutement
South Carolina
Prisma Health Greenville Memorial Hospital, Greenville, South Carolina, 29605, United States
Daniel Pasko, MD, Contact, 864-455-7000, [email protected]
En recrutement
Texas
University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States
Michal Fishel Bartal, MD, Contact, 832-325-7133, [email protected]
En recrutement